Cardiovascular Department, Intermountain Medical Center, Salt Lake City, Utah; University of Utah School of Medicine, Salt Lake City, Utah, USA.
Am J Cardiol. 2010 Apr 1;105(7):1030-5. doi: 10.1016/j.amjcard.2009.11.026. Epub 2010 Feb 13.
Right ventricular failure (RVF) after left ventricular assist device (LVAD) implantation appears to be associated with increased mortality. However, the determination of which patients are at greater risk of developing postoperative RVF remains controversial and relatively unknown. We sought to determine the preoperative risk factors for the development of RVF after LVAD implantation. The data were obtained for 175 consecutive patients who had received an LVAD. RVF was defined by the need for inhaled nitric oxide for >/=48 hours or intravenous inotropes for >14 days and/or right ventricular assist device implantation. An RVF risk score was developed from the beta coefficients of the independent variables from a multivariate logistic regression model predicting RVF. Destination therapy (DT) was identified as the indication for LVAD implantation in 42% of our patients. RVF after LVAD occurred in 44% of patients (n = 77). The mortality rates for patients with RVF were significantly greater at 30, 180, and 365 days after implantation compared to patients with no RVF. By multivariate logistic regression analysis, 3 preoperative factors were significantly associated with RVF after LVAD implantation: (1) a preoperative need for intra-aortic balloon counterpulsation, (2) increased pulmonary vascular resistance, and (3) DT. The developed RVF risk score effectively stratified the risk of RV failure and death after LVAD implantation. In conclusion, given the progressively growing need for DT, the developed RVF risk score, derived from a population with a large percentage of DT patients, might lead to improved patient selection and help stratify patients who could potentially benefit from early right ventricular assist device implantation.
左心室辅助装置(LVAD)植入术后右心衰竭(RVF)似乎与死亡率增加有关。然而,确定哪些患者发生术后 RVF 的风险更高仍然存在争议,且知之甚少。我们试图确定 LVAD 植入术后 RVF 发展的术前危险因素。该数据来自 175 例连续接受 LVAD 治疗的患者。RVF 通过需要吸入一氧化氮>48 小时或静脉内正性肌力药>14 天和/或需要植入右心室辅助装置来定义。从预测 RVF 的多变量逻辑回归模型的自变量的β系数中开发出 RVF 风险评分。我们患者中有 42%的患者以终末期心力衰竭(DT)为指征接受 LVAD 植入。LVAD 后 RVF 发生在 44%的患者(n=77)。与无 RVF 的患者相比,RVF 患者在植入后 30、180 和 365 天的死亡率显著更高。通过多变量逻辑回归分析,有 3 个术前因素与 LVAD 植入后 RVF 显著相关:(1)术前需要主动脉内球囊反搏,(2)肺血管阻力增加,以及(3)DT。开发的 RVF 风险评分可有效分层 LVAD 植入后 RV 衰竭和死亡的风险。总之,鉴于 DT 的需求不断增长,该 RVF 风险评分源自 DT 患者比例较大的人群,可能会有助于改进患者选择,并有助于分层潜在受益于早期右心室辅助装置植入的患者。